Psoriatic Arthritis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies

As per DelveInsight's assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Psoriatic Arthritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Psoriatic Arthritis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Psoriatic Arthritis Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Psoriatic Arthritis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Psoriatic Arthritis Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Psoriatic Arthritis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Psoriatic Arthritis Therapeutics Domain:
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Psoriatic Arthritis Therapeutics Analysis
There are approx. 50+ key companies developing therapies for Psoriatic Arthritis. Currently, Abbvie is leading the therapeutic market with its Psoriatic Arthritis drug candidates in the most advanced stage of clinical development.

The Leading Players in the Psoriatic Arthritis Therapeutics Market Include
3SBio, AbbVie, AbGenomics, Aclaris Therapeutics, Affibody, Akeso Biopharma, Alpine Immune Sciences, AltruBio, Amgen, Avotres, Bio-Thera Solutions, Biocad, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, CinnaGen, Cipla, DNX Biopharmaceuticals, Dong-A ST, Evelo, Formycon, Fresenius Kabi, Fujifilm Kyowa Kirin Biologics, Gilead Sciences, Hetero Biopharma, Innovimmune Biotherapeutics, Kangpu Biopharmaceuticals, Levolta Pharmaceuticals, Luye Pharma Group, Mycenax Biotech, Mylan, NeuClone, Pfizer, Polpharma Biologics, Qyuns Therapeutics, Sandoz, Shanghai Henlius Biotech, Sun Pharma Global, Synact Pharma, Torrent Pharmaceuticals, UCB Biopharma, XBiotech, Xbrane Biopharma, Zydus cadilla, and many others.

Psoriatic Arthritis Emerging and Marketed Drugs Covered in the Report Include:
• Bimekizumab: UCB Biopharma
• Deucravacitinib: BMS
• Ilumya (tildrakizumab-asmn): Sun Pharma
• Izokibep: Affibody AB
• Risankizumab: Abbvie
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Psoriatic Arthritis Current Treatment Patterns
4. Psoriatic Arthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Psoriatic Arthritis Late-Stage Products (Phase-III)
7. Psoriatic Arthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Psoriatic Arthritis Discontinued Products
13. Psoriatic Arthritis Product Profiles
14. Psoriatic Arthritis Key Companies
15. Psoriatic Arthritis Key Products
16. Dormant and Discontinued Products
17. Psoriatic Arthritis Unmet Needs
18. Psoriatic Arthritis Future Perspectives
19. Psoriatic Arthritis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.